HBOT for Thermal Burns

UHMS-approved for severe thermal burns to reduce infection and improve graft survival. Early initiation (within 24 hours) critical.

HBOT Hub — http://localhost:3003/conditions/burns · Printed October 11, 2026 · UHMS approved · Acute care · Early intervention

GRADE Evidence Rating

Quality: Low Weak recommendation

Cochrane 2004 found insufficient high-quality RCT evidence. UHMS approval rests on burn-centre observational experience.

Overview

HBOT for severe thermal burns is a UHMS-approved indication. Treatment aims to reduce burn progression, limit tissue loss in the "zone of stasis," decrease infection, and improve skin graft survival. Must be initiated within 24 hours of injury for maximum benefit.

How HBOT Works

HBOT in burns reduces oedema via mild vasoconstriction, enhances tissue oxygenation of the zone of stasis, promotes angiogenesis for repair, improves neutrophil-mediated bacterial killing, and supports skin graft take. Reduction in fluid resuscitation requirements has been documented in some studies.

Clinical Protocol

Typical protocol20–40 sessions at 2.0–2.4 ATA; early initiation critical
Evidence levelModerate — UHMS approved
FDA / regulatory statusFDA-approved indication

Standard burn HBOT: 2.0–2.4 ATA sessions started within 24 hours of injury. Initial frequency may be twice daily for the first 48 hours, then daily. Total course 20–40 sessions depending on burn severity and surgical course. Coordinated with burn surgery team.

Cautions & Considerations

Key Research

Indexed studies

Questions to Ask Your Doctor

  1. Am I a candidate for HBOT for this condition given my medical history and current treatments?
  2. What pressure (ATA) and session count would you recommend, and why?
  3. Is treatment at this centre UHMS-accredited? What is the chamber type (monoplace or multiplace)?
  4. What is the expected response rate and typical timeline for improvement?
  5. What are the specific contraindications and side-effect risks in my case?
  6. What is the expected cost and insurance coverage status?
  7. What alternative or complementary treatments should I consider?
  8. How will we measure whether treatment is working?